Exclusive Summary

• Backed by dual US-FDA and PIC/S GMP certifications, ensuring world-class quality and enabling fast-track registration globally.
• Despite patent expiration, the incredibly high API photochemical synthesis barrier creates a scarcity of generic competitors globally, offering a blue-ocean opportunity to challenge the originator (Duphaston).
• Targets a massive absolute market size, catering directly to ~190 million endometriosis patients globally and a booming demand for IVF luteal phase support.
• Offers significant cost-structure advantages over the premium-priced originator, guaranteeing high margins for distributors and strong competitiveness in public procurement tenders.